Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Setanaxib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 known ✓ | Q9NPH5 | 20/20 | 1.00 |
| ▸ | NOX1 known ✓ | Q9Y5S8 | 5/20 | 1.00 |
| ▸ | CYBB | P04839 | 5/20 | 1.00 |
| ▸ | NOX5 | Q96PH1 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.50 |
| ▸ | CYP2C8 | P10632 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Setanaxib SCHEMBL29375704 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| Setanaxib SCHEMBL29362127 | 1.00 | NOX4 (1.00) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612593 | 0.87 | NOX4 (0.77) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL16612522 | 0.86 | NOX4 (0.75) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302255 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5 | |
| SCHEMBL16612222 | 0.85 | NOX4 (0.74) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931735 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL29523003 | 0.84 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL1302943 | 0.83 | NOX4 (0.72) | NOX4CYBBNOX1NOX5CYP3A4 | |
| SCHEMBL14931788 | 0.82 | NOX4 (0.69) | NOX4CYBBNOX1NOX5CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 121 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-RE50878-E1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-05-05 | — | — | US | claimed |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2026-01-22 | — | — | US | claimed |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-10-31 | — | — | US | claimed |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2024-06-18 | — | — | US | claimed |
| WO-2023217764-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2023-11-16 | — | — | WO | claimed |
| US-20220259302-A1 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | UNIV VANDERBILT (US) | 2022-08-18 | — | — | US | claimed |
| EP-3946297-A1 | HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASES INHIBITORS AND USES IN TREATING CANCER | Emory University (US) | 2022-02-09 | — | — | EP | claimed |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2021-06-17 | — | — | US | claimed |
| US-20200354445-A1 | METHODS AND COMPOSITIONS FOR THE IMPROVEMENT OF LYSOSOMAL FUNCTION AND TREATMENT OF NEURODEGENERATIVE DISEASE | VANDERBILT UNIVERSITY | 2020-11-12 | — | — | US | claimed |
| WO-2020205937-A1 | HYALURONIC ACID NANOPARTICLES COMPRISING NADPH OXIDASES INHIBITORS AND USES IN TREATING CANCER | EMORY UNIVERSITY (US) | 2020-10-08 | — | — | WO | claimed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | claimed |
| WO-2016189501-A1 | PROCESS FOR THE PREPARATION OF A NADPH OXIDASE INHIBITOR AND ITS POLYMORPHS AND USES THEREOF | GENKYOTEX SA (CH) | 2016-12-01 | — | — | WO | claimed |
| EP-3098220-A1 | PROCESS FOR THE PREPARATION OF A NADPH OXIDASE INHIBITOR AND ITS POLYMORPHS AND USES THEREOF | GenKyoTex SA (CH) | 2016-11-30 | — | — | EP | claimed |
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | CALLIDITAS THERAPEUTICS SUISSE SA (CH) | 2015-10-15 | — | — | US | claimed |
| US-9096588-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SA (CH) | 2015-08-04 | — | — | US | claimed |
| WO-2015049655-A1 | COMPOUNDS USEFUL FOR THE TREATMENT OF PDE5 INHIBITOR-POORLY RESPONSIVE ERECTILE DYSFUNCTION | GENKYOTEX SA (CH) | 2015-04-09 | — | — | WO | claimed |
| EP-2857399-A1 | Compounds useful for the treatment of PDE5 inhibitor-poorly responsive erectile dysfunction | GenKyoTex SA (CH) | 2015-04-08 | — | — | EP | claimed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | claimed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | claimed |
| WO-2010035221-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2010-04-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150290208-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885NOX1 1/4885CYBB 3/4885 |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885NOX1 1/4885CYBB 3/4885 |
| US-20260021079-A1 | NOX INHIBITORS FOR USE IN THE TREATMENT OF ALPORT SYNDROME | NOX1, NOX5, NOX4 | NOX4 3/4885NOX1 1/4885CYBB 6/4885 |
| US-12011436-B2 | Use of NOX inhibitors for treatment of cancer | NOX1, NOX5, NOX3 | NOX4 5/4885NOX1 1/4885CYBB 6/4885 |
| US-20240358687-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | NOX4 5/4885NOX1 1/4885CYBB 6/4885 |
| US-20210177811-A1 | USE OF NOX INHIBITORS FOR TREATMENT OF CANCER | NOX1, NOX5, NOX3 | NOX4 5/4885NOX1 1/4885CYBB 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.